Effects and Mechanisms of Lonicerin Against Atopic Dermatitis: An Integration of Bioinformatics Analysis and Experimental Validation
The FASEB Journal · 2025
DOI: 10.1096/fj.202503375r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Hui Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, People's Republic of China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Computational Biology. Die Arbeit nennt 46 Literaturangaben. Gefördert von: The Research Start-Up Funding for the Affiliated Hospital of Southwest Medical University, The science and Technology Strategic Cooperation Programs of Luzhou Municipal People's Government and Southwest Medical University.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin condition that significantly diminishes the quality of life for affected individuals. Lonicerin (LON), a natural bioflavonoid, possesses immunomodulatory and anti‐inflammatory properties. Nevertheless, the potential protective effects of LON on AD, in addition to the underlying mechanisms involved, remain to be elucidated. In the current study, we investigated the therapeutic effects of LON in an AD mouse model induced by 1‐chloro‐2,4‐dinitrobenzene (DNCB) and tumor necrosis factor (TNF)‐α/interferon gamma (IFN)‐γ stimulated HaCaT cells. The results showed that LON significantly mitigated AD manifestations, such as restricting mast cell, CD4 + T, and CD8 + T cell infiltration, inhibiting serum IgE and IL‐6 concentrations, improving epidermis and dermis thicknesses, histamine release, scratching behavior, SCORAD index, and restoring epidermal barrier proteins. LON also reduced the expression levels of proinflammatory cytokines and chemokines in dorsal skin tissues and HaCaT cells. The analysis of the GSE32924 database, in conjunction with network pharmacology, disclosed that PPARα, JAK2, and STAT1 may potentially be the targets accountable for the therapeutic efficacy of LON. Furthermore, transcriptomics, immunofluorescence staining, PCR, Western blotting, and siRNA transfection, along with antagonist combinations, confirmed that LON regulated the skin inflammatory response involving PPARα activation and STAT1 inhibition. Taken together, our studies indicate that LON can suppress AD‐like skin inflammation both in vivo and in vitro. These findings imply that LON may serve as a possible alternative therapeutic treatment for AD or other skin‐related inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, People's Republic of China.
- Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
- Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
ORCID-Profile: Minghua Liu, Ge Zhao
Förderung
- The Research Start-Up Funding for the Affiliated Hospital of Southwest Medical University
- The science and Technology Strategic Cooperation Programs of Luzhou Municipal People's Government and Southwest Medical University
Zitieren
APA
Li, H., Zhu, W., Zhan, C., Gong, X., Liu, M., & Zhao, G. (2025). Effects and Mechanisms of Lonicerin Against Atopic Dermatitis: An Integration of Bioinformatics Analysis and Experimental Validation. The FASEB Journal. https://doi.org/10.1096/fj.202503375r
Vancouver
Li H, Zhu W, Zhan C, Gong X, Liu M, Zhao G. Effects and Mechanisms of Lonicerin Against Atopic Dermatitis: An Integration of Bioinformatics Analysis and Experimental Validation. The FASEB Journal. 2025. doi:10.1096/fj.202503375r
BibTeX
@article{Li2025,
author = {Li, Hui and Zhu, Wenjing and Zhan, Chenglin and Gong, Xiaofang and Liu, Minghua and Zhao, Ge},
title = {Effects and Mechanisms of Lonicerin Against Atopic Dermatitis: An Integration of Bioinformatics Analysis and Experimental Validation},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202503375r}
}
EUVIMED